Advances and challenges in diagnosis and management of skeletal metastases

Orthopedics

Volumn 29, Issue 7, 2006, Pages 609-620

  Papagelopoulos, Panayiotis J ^a   Savvidou, Olga D ^b   Galanis, Evanthia C ^c   Mavrogenis, Andreas F ^a   Jacofsky, David J ^c   Frassica, Frank J ^d   Sim, Franklin H ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Triasion Hospital   (Greece)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; AMITRIPTYLINE; ANASTROZOLE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CODEINE; DESIPRAMINE; EXEMESTANE; FENTANYL; FLUTAMIDE; FULVESTRANT; GABAPENTIN; GOSERELIN; HYDROCODONE; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; CANCER CONTROL; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; FUNCTIONAL ASSESSMENT; HUMAN; HYPOCALCEMIA; LONG TERM CARE; MINIMALLY INVASIVE SURGERY; NERVE BLOCK; NEUROPATHIC PAIN; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SPINAL CORD METASTASIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISCERAL METASTASIS;

EID: 33746428447     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20060701-01     Document Type: Review

References (87)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 suppl):1588-1594.
2. Rouleau P, Wenger D. Radiologic evaluation of metastatic bone disease. In: Menendez L, ed. Orthopaedic Knowledge Update. Musculoskeletal Tumors. Rosemont, Ill: American Academy of Orthopaedics Surgeons; 2002:313-322.
3. Frassica F, Frassica D. Metastatic bone disease: general considerations. In: Menendez L, ed. Orthopaedic Knowledge Update. Musculoskeletal Tumors. Rosemont, Ill: American Academy of Orthopaedics Surgeons; 2002:305-312.
4. Schachar NS. An update on the nonoperative treatment of patients with metastatic bone disease. Clin Orthop. 2001; 382:75-81.
5. Sim FH. Metastatic Bone Disease: Philosophy of treatment. Orthopedics. 1992; 15:541-44.
6. Frassica FJ, Ross A. Pathology of Bone and Joint Disorders: With Clinical and Radiographic Correlation. Philadelphia, Pa: WB Saunders; 1998.
7. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940; 112:138-149.
8. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop. 1995; 312:34-44.
9. Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop. 2000; 373:104-114.
10. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996; 98:1544-1549.
11. Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am. 1993; 75:1276-1281.
12. Simon MA, Nachman J. The clinical utility of pre-operative therapy for sarcomas. J Bone Joint Surg Am. 1986; 68:1458-1463.
13. Galasko CS. Diagnosis of skeletal metastasis and assessment of response to treatment. Clin Orthop. 1995; 312:64-75.
14. Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 1999; 86:533-537.
15. Corcoran RJ, Thrall JH, Kyle RW, Kaminski RJ, Johnson MC. Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology. 1976; 121(3 Pt 1):663-667.
16. Hendrix RW, Rogers LF, Davis TM Jr. Cortical bone metastases. Radiology. 1991; 181:409-413.
17. Traill Z, Richards MA, Moore NR. Magnetic resonance imaging of metastatic bone disease. Clin Orthop. 1995; 312:76-88.
18. Vanel D, Bittoun J, Tardivon A. MRI of bone metastases. Eur Radiol. 1998; 8:1345-1351.
19. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol. 1999; 25:3-23.
20. Chan Y, Chan K, Lam W, Metreweli C. Comparison of whole body MRI and radioisostope bone scintigram for skeletal metastases detection. Chin Med J. 1997; 110:485-489.
21. Eustace S, Tello R, DeCarvalho V et al. A comparison of whole-body turbo STIR MR imaging and planar 99m Tc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol. 1997; 169:1655-1661.
22. Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging. 2000; 11:343-350.
23. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998; 39:250-254.
24. Enneking WF, Spanier SS, Goodman MA. A system for surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980; 153:106-120.
25. Harrington KD. Metastatic disease of the spine. J Bone Joint Surg Am. 1986; 68:1110-1115.
26. Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine. 1990; 15:1100-1103.
27. Tatsui H, Onomura I, Morishita S, Oketa M, Inoue T. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine. 1996; 18:2143-2148.
28. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru J. Surgical Strategy for spinal Metastases. Spine. 2001; 26:298-306.
29. Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000; 50:70-116.
30. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, et al. Minimally invasive techniques in orthopedic oncology: radiofrequency and laser ablation. Orthopedics. 2005; 28:563-568.
31. Frassica DA, Gunderson LL. Principles of radiation therapy in the treatment of bone metastases. Orthopedics. 1992; 15:579-581.
32. Townsend PW, Smalley SR, Cozad SC, Rosenthal HG, Hassanein RE. Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. Int J Radiat Oncol Biol Phys. 1995; 31:43-49.
33. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991; 27:954-958.
34. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153 Sm-ethylenediaminetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997; 33:1583-1591.
35. Gronemeyer DH, Schirp SS, Gevargez A. Image-guided radiofrequency ablation of spinal tumors: preliminary experience with an expandable array electrode. Cancer J. 2002; 8:33-39.
36. Coleman RE. Management of bone metastases. Oncologist. 2000; 5:463-470.
37. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16:593-602
38. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16:2038-2044.
39. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2002; 10:52-62.
40. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003; 9:2394-2399.
41. Coleman RE, Rosen LS, Gordon D, et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res Treat. 2002; 76:s95.
42. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21:3150-3157.
43. Galanis E. Supportive measures. Carcinoma metastatic to bone. In: Menendez L, ed. Orthopaedic Knowledge Update. Musculoskeletal Tumors. Rosemont, Ill: American Academy of Orthopaedics Surgeons; 2002:331-341.
44. Nabholtz JM, Buzdar A, Pollak M, et al. Anastazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000; 18:3758-3767.
45. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19:2596-2606.
46. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003; 98:229-238.
47. Martinetti A, Ferrari L, Celio L, et al. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. J Steroid Biochem Mol Biol. 2000; 75:65-73.
48. Mauriac L, Coste P, Richaud P, Lamarche P, Mage P, Bonichon F. Clinical study of an LH-RH agonist (ICI 1118.630, Zoladex) in the treatment of prostatic cancer. Am J Clin Oncol. 1988; 11(suppl 2):S117-S119.
49. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999; 17:2027-2038.
50. Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford Textbook Of Palliative Medicine. 2nd ed. New York, NY: Oxford University Press; 1998:361-390.
51. Papagelopoulos PJ. Carcinoma metastatic to bone: nonsurgical management. In: Menendez L. Orthopaedic Knowledge Update. Musculoskeletal Tumors. Rosemont, Ill: American Academy of Orthopaedics Surgeons; 2002:343-348.
52. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop. 1989; 249:256-264.
53. Beals RK, Lawton GD, Snell WE. Prophylactic internal fixation of the femur in metastatic breast cancer. Cancer. 1971; 28:1350-1354.
54. Coran AG, Banks HH, Aliapoulios MA, Wilson RE. The management of padthologic fractures in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet. 1968; 127:1225-1230.
55. Fidler M. Prophylactic internal fixation of secondary neoplastic deposits in long bones. Br Med J. 1973; 1:341-343.
56. Parrish FF, Murray JA. Surgical treatment for secondary neoplastic fractures. A retrospective study of ninety-six patients. J Bone Joint Surg Am. 1970; 52:665-686.
57. Francis KC, Higinbotham NL, Carroll RE, Jacobs B, Graham WD. The treatment of pathological fractures of the femoral neck by resection. J Trauma. 1962; 2: 465-473.
58. McLaughlin HL. Intramedullary fixation of pathological fractures. Clin Orthop. 1953; 2:108-114.
59. Harrington KD, Sim FH, Enis JE, Johnston JO, Diok HM, Gristina AG. Methylmethacrylate as an adjunct in internal fixation of pathological fractures. Experience with three hundred and seventy-five cases. J Bone Joint Surg Am. 1976; 58:1047-1055.
60. Gitelis S, Sheinkop MB, Hammerberg K. The treatment of metastatic foci of the proximal femur: a retrospective review (abstract). Orthopaedic Transactions. 1981; 5:428.
61. Habermann ET, Sachs R, Stem RE, Hirsh DM, Anderson WJ Jr. The pathology and treatment of metastatic disease of the femur. Clin Orthop. 1982; 169:70-82.
62. Zickel RE, Mouradian WH. Intramedullary fixation of pathological fractures and lesions of the subtrochanteric region of the femur. J Bone Joint Surg Am. 1976; 58: 1061-1066.
63. Mickelson MR, Bonfiglio M. Pathological fractures in the proximal part of the femur treatment by Zickel-nail fixation. J Bone Joint Surg Am. 1976; 58:1067-1070.
64. Karachalios I, Atkins RM, Sarangi PP, Crichlow TP, Solomon L. Reconstruction nailing for pathological subtrochanteric fracrures with coexisting femoral shaft metastases. J Bone Joint Surg Br. 1993; 75:119-122.
65. Marti A, Fankhauser C, Frenk A, Cordey J, Gasser B. Biomechanical evaluation of the less invasive stabilization system for the internal fixation of distal femur fractures. J Orthop Trauma. 2001; 15:482-487.
66. Clarke HD, Damron TA, Sim FH. Head and neck replacement endoprosthesis for pathologic proximal femoral lesions. Clin Orthop. 1998; 353:210-217.
67. Cottias P, Jeanrot C, Vinh TS, Tomeno B, Anract P. Compilations and functional evaluation of 17 saddle prostheses for resection of periacetabular tumors. J Surg Oncol. 2001; 78:90-100.
68. Renard AJ, Veth RP, Schreuder HW, et al. The saddle prosthesis in pelvic primary and secondary musculoskeletal tumors: functional results at several postoperative intervals. Arch Orthop Trauma Surg. 2000; 120:188-194.
69. Stark A, Bauer HC. Reconstruction in metastatic destruction of the acetabulum. Support rings and arthroplasty in 12 patients. Acta Orthop Scand. 1996; 67:435-438.
70. Patterson FR, Peabody TD. Operative management of metastases to the pelvis and acetabulum. Orthop Clin North Am. 2000; 31:623-631.
71. Papagelopoulos PJ, Galanis EC, Greipp PR, Sim FH. Prosthetic hip replacement for pathologic or impending pathologic fractures in myeloma. Clin Orthop. 1997; 341:192-205.
72. Harrington KD. The management of acetabular insufficiency secondary to metastatic malignant disease. J Bone Joint Surg Am. 1981; 63:653-664.
73. Cotten A, Deprez X, Migaud H, Chabanne B, Duquesnoy B, Chastanet P. Malignant acetabular osteolyses: percutaneous infection of acrylic bone cement. Radiology. 1995; 197:307-310.
74. Papagelopoulos PJ, Mavrogenis AF, Kelekis AD, et al. Percutaneous osteoplasty for pelvic and spine metastases. Orthopedics. 2006; 29:315-323.
75. Gellad FE, Sadato N, Numaguchi Y, Levine AM. Vascular metastatic lesions of the spine: preoperative embolization. Radiology. 1990; 176:683-686.
76. Asdourian PL. Metastatic disease of the spine. In: Bridwell KH, DeWald RL, eds. The Textbook of Spinal Surgery. 2nd ed. Philadelphia, Pa: Lippincott-Raven-Raven Publishers; 1997:2007-2050.
77. McAfee PC, Zdeblick TA. Tumors of the thoracic and lumbar spine: surgical treatment via the anterior approach. J Spinal Disord. 1989; 2:145-154.
78. Siegal T, Siegal T. Current considerations in the management of neoplastic spinal cord compression. Spine. 1989; 14:223-228.
79. Weill A, Chiras J, Simon JM, Rose M, Sola-Martinez T, Enkaoua E. Spinal metastases: indication for and results of percutaneous injection of acrylic surgical cement. Radiology. 1996; 199:241-247.
80. Cortet B, Cotten A, Boutry N, et al. Percutaneous vertebroplasty in patients with osteolytic metastases or multiple myeloma. Revue du Rhumatisme (English ed). 1997; 64:177-183.
81. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655.
82. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncology. 1984; 2:187-193.
83. Lansky D, Butler JB, Waller FT. Using health status measures in the hospital setting: from acute care to 'outcomes management.' Med Care. 1992; 30(5 suppl):MS57-MS73.
84. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop. 1993; 286:241-246.
85. Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996; 5:508-516.
86. Clohisy DR, Le CT, Umen AJ. Measuring health status in patients with skeletal metastases treated by surgery Am Clin Oncol. 1997; 20:424-428.
87. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I, Conceptual framework and item selection. Med Care. 1992; 30:473-483.